Company: CMND
Filing Date: 2025-11-13
Form Type: 424B5
Source: 0001213900-25-109567
Chunk: 30

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-13
Form: 424B5
Chunk 30
---

payable by us.

We currently expect to use
the net proceeds from this offering for general corporate purposes, which may include operating expenses, research and development, including
clinical and pre-clinical testing of our product candidates, working capital, future acquisitions and general capital expenditures.

The amounts and schedule of
our actual expenditures will depend on multiple factors including the progress of our clinical development and regulatory efforts, the
status and results of the clinical trials, the pace of our partnering efforts in regard to manufacturing and commercialization and the
overall regulatory environment. Therefore, our management will retain broad discretion over the use of the proceeds from this offering.
We may ultimately use the proceeds for different purposes than what we currently intend. Pending any ultimate use of any portion of the
proceeds from this offering, if the anticipated proceeds will not be sufficient to fund all the proposed purposes, our management will
determine the order of priority for using the proceeds, as well as the amount and sources of other funds needed.

Pending our application of
the net proceeds from this offering, we plan to invest such proceeds in short-term, investment-grade, interest-bearing securities and
depositary institutions.

<div align='center'>DIVIDEND POLICY</div>

We have never declared or
paid any cash dividends to our shareholders of our Common Shares, and we do not anticipate or intend to pay cash dividends in the foreseeable
future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors, or our Board, in compliance
with applicable legal requirements and will depend on a number of factors, including future earnings, our financial condition, operating
results, contractual restrictions, capital requirements, business prospects, our strategic goals and plans to expand our business, applicable
law and other factors that our Board may deem relevant.

The Business Corporations
Act (British Columbia), as amended imposes further restrictions on our ability to declare and pay dividends. See “Description of
Securities—Dividend Rights” filed as Exhibit 2.2 to our most recent Annual Report on Form 20-F incorporated by reference herein
for additional information.

Payment of dividends may be
subject to Canadian withholding taxes. See “Item 10. – Additional Information – E. “Taxation — Material
Canadian Federal Income Tax Considerations” in our most recent Annual Report on Form 20-F incorporated by reference herein for additional
information.

<div align='center'>S-15

PLAN OF DISTRIBUTION</div>

We have arranged for